Chimpanzee-human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency postexposure prophylaxis.
about
An interaction between glutathione and the capsid is required for the morphogenesis of C-cluster enterovirusesAntiviral Activity of Pocapavir in a Randomized, Blinded, Placebo-Controlled Human Oral Poliovirus Vaccine Challenge Model.Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication.Development of Norwalk virus-specific monoclonal antibodies with therapeutic potential for the treatment of Norwalk virus gastroenteritis.A single chimpanzee-human neutralizing monoclonal antibody provides post-exposure protection against type 1 and type 2 polioviruses.Characterization of Poliovirus Neutralization Escape Mutants of Single-Domain Antibody Fragments (VHHs).Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display.Generation of Recombinant Antibodies Against Toxins and Viruses by Phage Display for Diagnostics and Therapy.Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding SiteCross-neutralizing human anti-poliovirus antibodies bind the recognition site for cellular receptor.The generation and evaluation of two panels of epitope-matched mouse IgG1, IgG2a, IgG2b and IgG3 antibodies specific for Plasmodium falciparum and Plasmodium yoelii merozoite surface protein 1-19 (MSP1(19)).Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and ProtectIntrafamilial spread of enterovirus infections at the clinical onset of type 1 diabetes.Newcastle Disease Virus-Based Vectored Vaccine against Poliomyelitis
P2860
Q28537710-537E55D7-C986-440A-9917-FE04740A3985Q33568783-CB221F65-32FF-45E9-A007-4B58106BE761Q34443617-B358D3F2-DD0A-402C-B685-7F504D2219B7Q34778430-C0ED8BA5-F508-4075-89E4-5C65110287FFQ35228866-FDFED93A-3B79-4487-8287-E4B7FCFD6780Q35859875-8A691369-D259-40AA-9DA5-0B3AA40B7BCCQ36023082-F6B9C47E-0401-48DE-8090-902A6FEB8654Q36033286-C7D0153D-B57B-4111-B0DD-75B26483165FQ36590540-02DA2D64-1F3D-4633-BCC3-743C93E2C8E1Q37395077-D02B977C-7CD0-47D7-A079-FB8EE5918548Q39395136-41FD83CD-12FB-45E1-BF66-19028ADF7072Q39574405-E98C8A70-2A64-4553-97C9-BA1043BAF8C3Q44828250-0CBDB0FB-709D-45D8-BE10-38B900274F6EQ57169065-A483F5F8-F615-49FE-AC79-9B4039FA9482
P2860
Chimpanzee-human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency postexposure prophylaxis.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Chimpanzee-human monoclonal an ...... ency postexposure prophylaxis.
@ast
Chimpanzee-human monoclonal an ...... ency postexposure prophylaxis.
@en
type
label
Chimpanzee-human monoclonal an ...... ency postexposure prophylaxis.
@ast
Chimpanzee-human monoclonal an ...... ency postexposure prophylaxis.
@en
prefLabel
Chimpanzee-human monoclonal an ...... ency postexposure prophylaxis.
@ast
Chimpanzee-human monoclonal an ...... ency postexposure prophylaxis.
@en
P2093
P2860
P356
P1433
P1476
Chimpanzee-human monoclonal an ...... ency postexposure prophylaxis.
@en
P2093
Alexander Neverov
Andrew Sebrell
Diana Kouiavskaia
Eugenia Dragunsky
Gennady Rezapkin
Konstantin Chumakov
Michelle Makiya
Robert Purcell
Zhaochun Chen
P2860
P304
P356
10.1128/JVI.02553-10
P577
2011-02-23T00:00:00Z